PHAT - Phathom Pharmaceuticals, Inc. Common Stock

Day	1m	10m	60m	PreMarket	Market	AfterHours	Gap
12.53 0.92 (7.34%)	---	---	---	-0.12 (-0.96%)	0.99 (7.95%)	0.34 (2.57%)	0.34 (2.57%)

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Category: PHARMACEUTICAL PREPARATIONS

Market Period: Closed

Earnings & Ratios

Basic EPS:: -1.05
Diluted EPS:: -1.05
Basic P/E:: -12.8095
Diluted P/E:: -12.8095
RSI(14) 1m:: 0.0
VWAP:: 13.46
RVol:: 1.4181

Events

Period	Kind	Movement	Occurred At
Day	Price increase day	13.82 +1.29 (+10.3%)	Oct 15 13:59
1m	Price increase 1m	13.37 +0.23 (+1.75%)	Oct 15 10:40
1m	Price increase 1m	13.16 +0.25 (+1.94%)	Oct 15 10:39
1m	Price increase 1m	13.01 +0.16 (+1.21%)	Oct 15 10:37
10m	Price increase 10m	13.01 +0.49 (+3.92%)	Oct 15 10:37